Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update
14. Mai 2024 08:05 ET | Palisade Bio, Inc.
– Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end – Sufficient cash on hand to...